Crestline Management’s Travere Therapeutics TVTX Stock Holding History

Crestline Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-185,840	Closed	-$3.24M	–	602
2024 Q4	$3.24M	Buy	185,840 +65,115	+54%	+$1.15M	0.11%	210
2024 Q3	$1.69M	Buy	120,725 +17,372	+17%	+$181K	0.09%	210
2024 Q2	$850K	Buy	103,353 +19,454	+23%	+$131K	0.07%	154
2024 Q1	$647K	Buy	83,899 +2,476	+3%	+$20.9K	0.06%	154
2023 Q4	$732K	Buy	81,423 +20,002	+33%	+$146K	0.06%	152
2023 Q3	$549K	Hold	61,421	–	–	0.06%	137
2023 Q2	$943K	Buy	61,421 +1,421	+2%	+$25.8K	0.1%	144
2023 Q1	$1.35M	Buy	+60,000	New	+$1.28M	0.16%	114
2022 Q3	–	Sell	-44,119	Closed	-$1.07M	–	266
2022 Q2	$1.07M	Buy	44,119 +5,474	+14%	+$138K	0.14%	119
2022 Q1	$996K	Buy	+38,645	New	+$1.03M	0.12%	142

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Crestline Management's TVTX Position: Q1 2025 in Review

Crestline Management sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 185,840 shares — an estimated $3.24M sold.

Crestline Management first reported a position in TVTX in Q1 2022 and held it in 10 quarters. The position peaked at $3.24M in Q4 2024. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

Crestline Management reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 185,840 Travere Therapeutics shares in Q1 2025, an estimated $3.24M.
Crestline Management first reported a position in Travere Therapeutics in Q1 2022 and held it in 10 quarters.
Crestline Management's Travere Therapeutics position peaked at $3.24M in Q4 2024.
218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.